Drug Profile
Research programme: immunology, inflammation and cardiometabolic disease therapeutics - BioMotiv/Takeda
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator BioMotiv
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Immunological disorders; Inflammation
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Oct 2018 No recent reports of development identified for research development in Immunological-disorders in USA
- 28 Oct 2018 No recent reports of development identified for research development in Inflammation in USA